Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib

BACKGROUND/PURPOSE: Lenvatinib is a first-line treatment for unresectable hepatocellular carcinoma (uHCC). We assessed the value of early alpha-fetoprotein (AFP) response for predicting clinical outcomes with lenvatinib treatment in patients with HBV-related uHCC and elevated AFP levels. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bo, Shang, Xiao, Shi, Jin-Yu, Cui, Guo-Zhen, Li, Xi, Wang, Nan-Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893311/
https://www.ncbi.nlm.nih.gov/pubmed/35251977
http://dx.doi.org/10.3389/fonc.2022.807189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893311/
https://www.ncbi.nlm.nih.gov/pubmed/35251977
http://dx.doi.org/10.3389/fonc.2022.807189

Ejemplares similares